These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21899912)

  • 1. Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes.
    Nomiyama T; Akehi Y; Takenoshita H; Nagaishi R; Terawaki Y; Nagasako H; Kudo T; Kodera T; Kobayashi K; Urata H; Yanase T;
    Diabetes Res Clin Pract; 2012 Feb; 95(2):e27-8. PubMed ID: 21899912
    [No Abstract]   [Full Text] [Related]  

  • 2. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes.
    Maeda H; Kubota A; Tanaka Y; Terauchi Y; Matsuba I;
    Diabetes Res Clin Pract; 2012 Jan; 95(1):e20-2. PubMed ID: 22055835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sitagliptin--another option for managing type 2 diabetes in dialysis patients?
    St Peter WL; Weinhandl ED; Flessner MF
    Am J Kidney Dis; 2013 Apr; 61(4):532-5. PubMed ID: 23497767
    [No Abstract]   [Full Text] [Related]  

  • 4. One-year real-life efficacy of sitagliptin revealed importance of concomitant pioglitazone use in Japanese patients with type 2 diabetes mellitus.
    Suzuki A; Yoshimura N; Mashimo Y; Numakura M; Fujimaki Y; Maeda T; Ishikawa T; Fujimori S; Eto K
    Diabetes Metab Syndr; 2013; 7(3):143-7. PubMed ID: 23953179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Rhee EJ; Lee WY; Min KW; Shivane VK; Sosale AR; Jang HC; Chung CH; Nam-Goong IS; Kim JA; Kim SW;
    Diabetes Obes Metab; 2013 Jun; 15(6):523-30. PubMed ID: 23320436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes.
    Matsubara J; Sugiyama S; Akiyama E; Iwashita S; Kurokawa H; Ohba K; Maeda H; Fujisue K; Yamamoto E; Kaikita K; Hokimoto S; Jinnouchi H; Ogawa H
    Circ J; 2013; 77(5):1337-44. PubMed ID: 23386232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of concomitant drugs on sitagliptin-mediated improvement in glycemic control in Japanese patients with type 2 diabetes.
    Hirata T; Inukai K; Morimoto J; Katayama S; Ishida H
    Prim Care Diabetes; 2014 Oct; 8(3):265-70. PubMed ID: 24530100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1).
    Lumb AN; Gallen IW
    Diabet Med; 2009 Feb; 26(2):189-90. PubMed ID: 19236626
    [No Abstract]   [Full Text] [Related]  

  • 9. [Type 2 diabetes: interview with Prof. Stephan Matthaei. Reaching HbA1c target value while preventing hypoglycemia].
    Matthaei S
    MMW Fortschr Med; 2009 Oct; 151(42):54. PubMed ID: 19938786
    [No Abstract]   [Full Text] [Related]  

  • 10. A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus--a randomized controlled trial START-J study.
    Hibuse T; Maeda N; Kishida K; Kimura T; Minami T; Takeshita E; Hirata A; Nakagawa Y; Kashine S; Oka A; Hayashi M; Nishizawa H; Funahashi T; Shimomura I
    Cardiovasc Diabetol; 2014 May; 13():96. PubMed ID: 24884787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combination antidiabetic therapy. Better control of blood glucose values].
    Bischoff A
    MMW Fortschr Med; 2009 Oct; 151(42):55. PubMed ID: 19938787
    [No Abstract]   [Full Text] [Related]  

  • 12. Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Erol A
    Clin Ther; 2008 Apr; 30(4):785-6; author reply 786. PubMed ID: 18498926
    [No Abstract]   [Full Text] [Related]  

  • 13. Primary objective of study of sitagliptin in patients with ESRD on dialysis.
    Arjona Ferreira JC; Golm GT; Goldstein BJ
    Am J Kidney Dis; 2013 Sep; 62(3):642. PubMed ID: 23972060
    [No Abstract]   [Full Text] [Related]  

  • 14. In reply to 'Primary objective of study of sitagliptin in patients with ESRD on dialysis'.
    St Peter WL; Weinhandl ED; Flessner MF
    Am J Kidney Dis; 2013 Sep; 62(3):642-3. PubMed ID: 23972059
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of sitagliptin monotherapy on serum total ghrelin levels in people with type 2 diabetes.
    Öz Ö; Kıyıcı S; Ersoy C; Cander S; Yorulmaz H; Gül CB; Ünal OK; Sarandol E; Kırhan E; Sığırlı D; Ertürk E; Tuncel E; Imamoğlu S
    Diabetes Res Clin Pract; 2011 Nov; 94(2):212-6. PubMed ID: 21855160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin.
    Kim HS; Shin JA; Lee SH; Kim ES; Cho JH; Son HY; Yoon KH
    Diabetes Technol Ther; 2013 Oct; 15(10):810-6. PubMed ID: 24050737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride.
    Umayahara R; Yonemoto T; Kyou C; Morishita K; Ogawa T; Taguchi Y; Inoue T
    Endocr J; 2014; 61(12):1163-70. PubMed ID: 25168659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting steady-state HbA1c responses to sitagliptin in patients with type 2 diabetes mellitus.
    Kanazu S; Horie Y; Narukawa M; Nonaka K; Taniguchi T; Arjona Ferreira JC; Takeuchi M
    Diabetes Obes Metab; 2009 Aug; 11(8):813-8. PubMed ID: 19476471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy.
    Shimoda S; Iwashita S; Ichimori S; Matsuo Y; Goto R; Maeda T; Matsuo T; Sekigami T; Kawashima J; Kondo T; Matsumura T; Motoshima H; Furukawa N; Nishida K; Araki E
    Endocr J; 2013; 60(10):1207-14. PubMed ID: 23912974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.
    Signorovitch JE; Wu EQ; Swallow E; Kantor E; Fan L; Gruenberger JB
    Clin Drug Investig; 2011; 31(9):665-74. PubMed ID: 21819162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.